PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

ETH technical analysis shows $20B Open Interest and rising leverage. With $123B near cost basis, Ethereum may face sharp ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Pursuant to the Facilities Agreement, NowVertical UK Ltd. and NowVertical Group, Inc., as borrowers, have access to credit facilities of up to $18 million (together, the " Facilities ”) which may be ...

According to data from CoinGecko, the Solana meme market capitalization stands at $11.5 billion as of June 2025, signaling ...

New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions ...

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC: London, UK Friday, May 30, 2025, 15:00 Hrs [IST] ...

Discover the future of data & AI driven stock trading platforms shaping smarter, data-powered investment decisions. AI and ...

At least twice as many patients on the approved spesolimab dose maintain improvement in skin symptoms and quality of life ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Backers of Jena, Germany-based Inflarx NV have turned their attention to the rest of the pipeline after the stock-jolting news from an independent data monitoring committee (DMC) responsible for the ...